http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2695167-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a60559e5784c59f0119d0cf1c3455f2b
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-6615
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-232
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-661
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-25
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-06
filingDate 2007-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8e9c25f3887ddcbf1fd236eb66869d1c
publicationDate 2008-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CA-2695167-A1
titleOfInvention Methods for the treatment of elevated cholesterol levels
abstract Use of a one or more of the following compounds: DHAP;1-acyl-DHAP;1-alkyl-DHAP; 1-alkyl-G3P; 1-alkyl, 2-acyl-G3P; 1-alkyl, 2-acyl-glycerol; 1-alkyl, 2-acyl-GPE, 1-alkyl, diacyl glycerol (sn-1=16:0, sn-2=DHA, sn-3=DHA) (sn-1 position has an alkyl ether bond, sn-2 and sn-3 positions have acyl bonds); 1-alkyl diacyl glycerol (sn-1=16:0, sn-2=18:1, sn-3=18:1) (sn-1 position has an alkyl ether bond, sn-2 and sn-3 positions have acyl bonds); triacyl glycerol (sn-1=16:0, sn-2=DHA, sn-3=DHA) (all three positions have acyl bonds); and triacyl glycerol (sn-1=16:0, sn-2=18:1, sn-3=18:1) (all three positions have acyl bonds), including pharmaceutically acceptable salts thereof, for lowering cholesterol in a patient in need thereof. Also described is the use of an ethanolamine plasmalogen elevating therapeutic agent for the treatment of a subject diagnosed with high cholesterol and decreased levels of one or more ethanolamine plasmalogen. In one particular embodiment the ethanolamine plasmalogen elevating therapeutic agent is: (see formula 5a)
priorityDate 2007-02-08-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419507953
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID700
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458393336
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5284499
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID753
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID455858454
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID668
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID408196011
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3283
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID457673783
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1061
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419587765
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11146
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419483691
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24905353
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5997
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1015
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID407850362
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419483452
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559261
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID411550719
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419482560
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID407443042

Total number of triples: 40.